4.1 Article

Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models

期刊

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 3, 期 6, 页码 1381-1390

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.0c00180

关键词

asthma; MIDD0301; bronchodilation; airway hyperresponsiveness

资金

  1. National Institutes of Health (USA) [R41HL147658, R01HL118561, R01GM065281, K08HL140102]
  2. Louis V. Gerstner, Jr. Scholar Award
  3. University of Wisconsin-Milwaukee
  4. University of Wisconsin-Milwaukee Research Foundation (Catalyst grant)
  5. Lynde and Harry Bradley Foundation
  6. Richard and Ethel Herzfeld Foundation
  7. National Science Foundation, Division of Chemistry [CHE-1625735]

向作者/读者索取更多资源

We report the relaxation of methacholine-constricted airways with nebulized MIDD0301, a positive allosteric gamma-aminobutyric acid type A receptor (GABA(A)R) modulator. The therapeutic efficacy of nebulized MIDD0301 in reducing airway resistance was investigated in spontaneous breathing mice using a whole-body plethysmograph and in unconscious mice using a forced oscillation technique. Prophylactic nebulized MIDD0301 reduced subsequent methacholine-induced bronchoconstriction in ovalbumin and house dust mite allergic asthma models and in normal mice. Nebulized MIDD0301 exhibited comparable or better therapeutic potency compared to nebulized albuterol and oral montelukast. Prophylactic nebulized MIDD0301 was also effective in reducing bronchoconstriction, comparable to nebulized albuterol or fluticasone, in a steroid resistant asthma mouse model induced by intratracheal installation of lipopolysaccharide and interferon-gamma. Oral dexamethasone was ineffective in this model. Nebulized MIDD0301 was also effective in reversing bronchospasm when dosed after methacholine challenge comparable to albuterol. Pharmacokinetic studies showed that about 0.06% of nebulized MIDD0301 entered the mouse lung when using a whole body plethysmograph and therapeutic levels were sustained in the lung for at least 25 min. Consistent with previous reports on orally dosed MIDD0301, high doses of nebulized MIDD0301 resulted in minimal brain exposure and thus no observable adverse sensorimotor or respiratory depression effects occurred. In addition, no adverse cardiovascular effects were observed following 100 mg/kg i.p. dosing. These results further demonstrate that charged imidazodiazepine MIDD0301 can selectively target lung GABA(A)R without adverse motor, cardiovascular, or respiratory effects and inhaled dosing is effective in reducing bronchoconstriction in allergen and infectious lung inflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据